- Home
- ENTX vs DTF Comparison
ENTX vs DTF Comparison
Compare ENTX & DTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- DTF
- Stock Information
- Founded
- ENTX 2010
- DTF 1991
- Country
- ENTX Israel
- DTF United States
- Employees
- ENTX N/A
- DTF N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- DTF Investment Managers
- Sector
- ENTX Health Care
- DTF Finance
- Exchange
- ENTX Nasdaq
- DTF Nasdaq
- Market Cap
- ENTX 67.2M
- DTF 79.5M
- IPO Year
- ENTX 2018
- DTF N/A
- Fundamental
- Price
- ENTX $2.25
- DTF $11.21
- Analyst Decision
- ENTX Strong Buy
- DTF
- Analyst Count
- ENTX 1
- DTF 0
- Target Price
- ENTX $10.00
- DTF N/A
- AVG Volume (30 Days)
- ENTX 54.3K
- DTF 21.1K
- Earning Date
- ENTX 11-08-2024
- DTF 01-01-0001
- Dividend Yield
- ENTX N/A
- DTF 3.64%
- EPS Growth
- ENTX N/A
- DTF N/A
- EPS
- ENTX N/A
- DTF 0.44
- Revenue
- ENTX $99,000.00
- DTF N/A
- Revenue This Year
- ENTX N/A
- DTF N/A
- Revenue Next Year
- ENTX N/A
- DTF N/A
- P/E Ratio
- ENTX N/A
- DTF $24.34
- Revenue Growth
- ENTX 607.14
- DTF N/A
- 52 Week Low
- ENTX $0.52
- DTF $10.29
- 52 Week High
- ENTX $3.35
- DTF $11.19
- Technical
- Relative Strength Index (RSI)
- ENTX 68.35
- DTF 42.00
- Support Level
- ENTX $2.02
- DTF $11.21
- Resistance Level
- ENTX $2.28
- DTF $11.34
- Average True Range (ATR)
- ENTX 0.17
- DTF 0.06
- MACD
- ENTX 0.04
- DTF -0.01
- Stochastic Oscillator
- ENTX 77.01
- DTF 9.52
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTFTax-Free Income Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax consistent with preservation of capital. The fund seeks to achieve its investment objective by investing in a diversified portfolio of investment-grade tax-exempt obligations.